Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Sun Loo; Nicola Potter; Adam Ivey; Jenny O'Nions Dr; Roderick Moon; Jelena Jovanovic; Chun Yew Fong; Natasha S Anstee; Ing S Tiong; Jad Othman; Chong Chyn Chua; Hannah Renshaw; Robert Baker; Shaun Fleming; Nigel H Russell; David Ritchie; Ashish Bajel; Hsin-An Hou; Richard James Dillon; Andrew H Wei

doi:10.1182/blood.2024026605

Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia

Blood. 2024 Sep 24:blood.2024026605. doi: 10.1182/blood.2024026605. Online ahead of print.

Authors

Sun Loo¹, Nicola Potter², Adam Ivey³, Jenny O'Nions Dr⁴, Roderick Moon⁵, Jelena Jovanovic⁶, Chun Yew Fong⁷, Natasha S Anstee⁸, Ing S Tiong⁹, Jad Othman¹⁰, Chong Chyn Chua¹¹, Hannah Renshaw¹², Robert Baker¹³, Shaun Fleming¹⁴, Nigel H Russell¹⁵, David Ritchie¹⁶, Ashish Bajel¹⁷, Hsin-An Hou¹⁸, Richard James Dillon¹⁹, Andrew H Wei²⁰

Affiliations

¹ Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 3052, Australia.
² King's College, London, United Kingdom.
³ The Alfred Hospital, Melbourne, Australia.
⁴ University College London Hospitals NHS Foundation Trust, London, United Kingdom.
⁵ Alfred Health, Melbourne, Australia.
⁶ King's College London, London, United Kingdom.
⁷ Austin Health, Heidelberg, Australia.
⁸ Walter and Eliza Hall Institute of Medical Research, Parkville, Australia.
⁹ Peter MacCallum Cancer Centre, Melbourne, Australia.
¹⁰ Kings College London, London, United Kingdom.
¹¹ 2. The Walter and Eliza Hall Institute of Medical Research, Australia.
¹² UCLH, London, United Kingdom.
¹³ Health Services Laboratories, London, United Kingdom.
¹⁴ Alfred Health, Ashwood, Australia.
¹⁵ Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
¹⁶ Peter MacCallum Cancer Centre and Royal Melboure Hospital, Melbourne, Australia.
¹⁷ Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
¹⁸ National Taiwan University Hospital, Taipei, Taiwan.
¹⁹ King's College, London, London, United Kingdom.
²⁰ Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.

PMID: 39316646
DOI: 10.1182/blood.2024026605

Abstract

Pre-transplant detection of KMT2Ar MRD ≥0.001% by quantitative PCR was associated with significantly inferior post-transplant survival (2-year RFS 17% vs 59%; p=0.001) and increased cumulative incidence of relapse (2-year CIR 75% vs 25%, p=0.0004).